Cargando…

Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD

OBJECTIVES: Characterise the circulating inflammatory cytokine pattern among patients failing consecutive anti-tumour necrosis factor (anti-TNF) and anti-integrin treatments to identify predictors of response. METHODS: A retrospective single-centre cohort study of 28 patients with inflammatory bowel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soendergaard, Christoffer, Seidelin, Jakob Benedict, Steenholdt, Casper, Nielsen, Ole Haagen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001911/ https://www.ncbi.nlm.nih.gov/pubmed/29915667 http://dx.doi.org/10.1136/bmjgast-2018-000208

Ejemplares similares

Impact of T300A Variant of ATG16L1 on Antibacterial Response, Risk of Culture Positive Infections, and Clinical Course of Crohn's Disease
por: Salem, Mohammad, et al.
Publicado: (2015)

A blood-based prognostic biomarker in IBD
por: Biasci, Daniele, et al.
Publicado: (2019)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Identifying and understanding disease burden in patients with inflammatory bowel disease
por: Christensen, Katrine Risager, et al.
Publicado: (2022)

Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD
por: Selinger, Christian Philipp, et al.
Publicado: (2021)

Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
por: Bethge, Johannes, et al.
Publicado: (2017)

Fungal microbiota dysbiosis in IBD
por: Sokol, Harry, et al.
Publicado: (2017)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report
por: Holmstroem, Rikke Boedker, et al.
Publicado: (2022)

HLA-DR(hi) and CCR9 Define a Pro-Inflammatory Monocyte Subset in IBD
por: Linton, Ludvig, et al.
Publicado: (2012)

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
por: Grišić, Ana‐Marija, et al.
Publicado: (2021)

Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis
por: Hamel, Blaise, et al.
Publicado: (2018)

Factors influencing the outcome of vedolizumab treatment: Real‐life data with objective outcome measurements
por: Mader, Orla, et al.
Publicado: (2021)

Food avoidance and fasting in patients with inflammatory bowel disease: Experience from the Nancy IBD nutrition clinic
por: Bonsack, Olivier, et al.
Publicado: (2023)

Preclinical IBD: One more piece of the puzzle
por: Agrawal, Manasi, et al.
Publicado: (2023)

Modulation of cytokine patterns and microbiome during pregnancy in IBD
por: van der Giessen, Janine, et al.
Publicado: (2020)

Surfing the web as a patient with IBD: New horizons
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2023)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Life in lockdown: experiences of patients with IBD during COVID-19
por: Harris, Richard James, et al.
Publicado: (2020)

IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology
por: Jones, Gareth-Rhys, et al.
Publicado: (2019)

BSG 2024 IBD guidelines protocol (standard operating procedures)
por: Gordon, Morris, et al.
Publicado: (2023)

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
por: Feagan, B. G., et al.
Publicado: (2016)

Current smoking habits in British IBD patients in the age of e-cigarettes
por: Chong, Chui, et al.
Publicado: (2019)

Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands
por: de Bock, Ellen, et al.
Publicado: (2021)

Whole exome sequencing analyses reveal gene–microbiota interactions in the context of IBD
por: Hu, Shixian, et al.
Publicado: (2021)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
por: Zoller, Heinz, et al.
Publicado: (2023)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD
por: Lee, Thomas, et al.
Publicado: (2017)

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
por: Koelink, Pim J, et al.
Publicado: (2020)

Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire
por: Bodger, Keith, et al.
Publicado: (2014)

Effectiveness of disease-specific cognitive–behavioural therapy on depression, anxiety, quality of life and the clinical course of disease in adolescents with inflammatory bowel disease: study protocol of a multicentre randomised controlled trial (HAPPY-IBD)
por: van den Brink, Gertrude, et al.
Publicado: (2016)

Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD
por: Gaujoux, Renaud, et al.
Publicado: (2019)

Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study
por: Dragoni, Gabriele, et al.
Publicado: (2023)

Inflammatory bowel diseases in Faroese‐born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development
por: Hammer, T., et al.
Publicado: (2017)

A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
por: Reinisch, Walter, et al.
Publicado: (2013)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Risk factors for developing colorectal cancer in Japanese patients with ulcerative colitis: a retrospective observational study—CAPITAL (Cohort and Practice for IBD total management in Kyoto-Shiga Links) study I
por: Yoshino, Takuya, et al.
Publicado: (2016)

Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC
por: Starr, Amanda E, et al.
Publicado: (2017)

Changing paradigms in management of inflammatory bowel disease
por: Mao, Ren, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n5p31ivbpb13hd36b4704fdim9